Secondary analysis of 73 adults with functional dyspepsia from the TENDER trial: mean annual costs were €12,192, mostly indirect (€10,240). Poorer disease-specific quality of life was associated with higher costs; symptom severity, anxiety and depression were not.
Secondary analysisn = 73
Bosch et al. Characterising the Economic Burden of Functional Dyspepsia: A Cost-of-Illness Study of Direct and Indirect Costs